phone

Myasthenia Gravis - Pipeline Review, H2 2017

  • Published Date: 18 Jul 2017
  • Number of Pages: 122
  • Category: Pharmaceuticals
  • Country: Global
Myasthenia Gravis - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Myasthenia Gravis - Pipeline Review, H2 2017, provides an overview of the Myasthenia Gravis (Immunology) pipeline landscape.

Myasthenia gravis is autoimmune neuromuscular disease characterized by weakness and rapid fatigue of any of the muscles under voluntary control. Symptoms include drooping of one or both eyelids, diplopia and difficulty swallowing, chewing and speaking. Treatment includes immunosuppressants, corticosteroids and surgery.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Myasthenia Gravis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Myasthenia Gravis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myasthenia Gravis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Myasthenia Gravis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 5, 4, 11 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Myasthenia Gravis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Myasthenia Gravis (Immunology).
- The pipeline guide reviews pipeline therapeutics for Myasthenia Gravis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Myasthenia Gravis (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Myasthenia Gravis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Myasthenia Gravis (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Myasthenia Gravis (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Myasthenia Gravis (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Publisher Name : Global Markets Direct

Introduction 6
Global Markets Direct Report Coverage 6
Myasthenia Gravis - Overview 7
Myasthenia Gravis - Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Pipeline by Universities/Institutes 12
Products under Development by Companies 13
Products under Development by Universities/Institutes 15
Myasthenia Gravis - Therapeutics Assessment 16
Assessment by Target 16
Assessment by Mechanism of Action 18
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Myasthenia Gravis - Companies Involved in Therapeutics Development 24
Achillion Pharmaceuticals Inc 24
Akari Therapeutics Plc 24
Alexion Pharmaceuticals Inc 25
Alpha Cancer Technologies Inc 25
Apellis Pharmaceuticals Inc 26
arGEN-X BV 26
BioMarin Pharmaceutical Inc 27
Bristol-Myers Squibb Company 27
CuraVac Inc 28
GlaxoSmithKline Plc 28
Grifols SA 29
HanAll Biopharma Co Ltd 29
Millennium Pharmaceuticals Inc 30
Neurotune AG 30
Novartis AG 31
Pfizer Inc 31
Ra Pharmaceuticals Inc 32
Regenesance BV 32
Shire Plc 33
Toleranzia AB 33
UCB SA 34
Myasthenia Gravis - Drug Profiles 35
abatacept - Drug Profile 35
ACT-101 - Drug Profile 43
amifampridine phosphate - Drug Profile 45
APL-2 - Drug Profile 51
belimumab - Drug Profile 54
bortezomib - Drug Profile 61
CFZ-533 - Drug Profile 69
CVMG-01 - Drug Profile 71
eculizumab - Drug Profile 73
efgartigimod alfa - Drug Profile 83
GL-2045 - Drug Profile 86
HL-161 - Drug Profile 88
immune globulin (human) - Drug Profile 89
methotrexate - Drug Profile 91
NT-1654 - Drug Profile 92
RA-101495 - Drug Profile 93
Recombinant Protein for Myasthenia Gravis - Drug Profile 96
Recombinant Protein to Target CHRNA1 for Myasthenia Gravis - Drug Profile 97
Recombinant Proteins to Inhibit Complement C5 for Myasthenia Gravis - Drug Profile 98
Regenemab - Drug Profile 99
rozanolixizumab - Drug Profile 100
SM-201 - Drug Profile 101
Small Molecules to Inhibit Complement Factor D for Myasthenia Gravis - Drug Profile 102
Synthetic Peptide to Inhibit Complement C5 for Autoimmune Disorders, Atypical Hemolytic Uremic Syndrome, Central Nervous System and Paroxysmal Nocturnal Hemoglobinuria - Drug Profile 103
TK-21 - Drug Profile 104
Vaccine for Myasthenia Gravis - Drug Profile 105
Vaccine for Myasthenia Gravis - Drug Profile 106
Myasthenia Gravis - Dormant Projects 107
Myasthenia Gravis - Discontinued Products 108
Myasthenia Gravis - Product Development Milestones 109
Featured News & Press Releases 109
Appendix 119
Methodology 119
Coverage 119
Secondary Research 119
Primary Research 119
Expert Panel Validation 119
Contact Us 119
Disclaimer 120

List Of Tables


Number of Products under Development for Myasthenia Gravis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Myasthenia Gravis - Pipeline by Achillion Pharmaceuticals Inc, H2 2017
Myasthenia Gravis - Pipeline by Akari Therapeutics Plc, H2 2017
Myasthenia Gravis - Pipeline by Alexion Pharmaceuticals Inc, H2 2017
Myasthenia Gravis - Pipeline by Alpha Cancer Technologies Inc, H2 2017
Myasthenia Gravis - Pipeline by Apellis Pharmaceuticals Inc, H2 2017
Myasthenia Gravis - Pipeline by arGEN-X BV, H2 2017
Myasthenia Gravis - Pipeline by BioMarin Pharmaceutical Inc, H2 2017
Myasthenia Gravis - Pipeline by Bristol-Myers Squibb Company, H2 2017
Myasthenia Gravis - Pipeline by CuraVac Inc, H2 2017
Myasthenia Gravis - Pipeline by GlaxoSmithKline Plc, H2 2017
Myasthenia Gravis - Pipeline by Grifols SA, H2 2017
Myasthenia Gravis - Pipeline by HanAll Biopharma Co Ltd, H2 2017
Myasthenia Gravis - Pipeline by Millennium Pharmaceuticals Inc, H2 2017
Myasthenia Gravis - Pipeline by Neurotune AG, H2 2017
Myasthenia Gravis - Pipeline by Novartis AG, H2 2017
Myasthenia Gravis - Pipeline by Pfizer Inc, H2 2017
Myasthenia Gravis - Pipeline by Ra Pharmaceuticals Inc, H2 2017
Myasthenia Gravis - Pipeline by Regenesance BV, H2 2017
Myasthenia Gravis - Pipeline by Shire Plc, H2 2017
Myasthenia Gravis - Pipeline by Toleranzia AB, H2 2017
Myasthenia Gravis - Pipeline by UCB SA, H2 2017
Myasthenia Gravis - Dormant Projects, H2 2017
Myasthenia Gravis - Discontinued Products, H2 2017

List Of Figures


Number of Products under Development for Myasthenia Gravis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Myasthenia Gravis - Pipeline Review, H2 2017 Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Myasthenia Gravis - Pipeline Review, H2 2017, provides an overview of the Myasthenia Gravis

View Report

EpiCast Report: Myasthenia Gravis - Epidemiology Forecast to 2024 market research report at USD 3995 and market update available at JSB Market Research.

View Report

Myasthenia Gravis Global Clinical Trials Review, H1, 2015 market research report at USD 2500 and market update available at JSB Market Research.

View Report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports